Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1767594 | 1.00 | LMNA (0.44) | LMNASMN1; SMN2MEN1KMT2ATHRB | |
| SCHEMBL28312506 | 0.79 | LMNA (0.46) | LMNASMN1; SMN2MEN1KMT2ATHRB | |
| SCHEMBL5375586 | 0.79 | ALDH1A1 (0.37) | MEN1KMT2ATHRBBLMTDP1 | |
| SCHEMBL964992 | 0.79 | LMNA (0.50) | LMNASMN1; SMN2MEN1KMT2ATHRB | |
| SCHEMBL17727043 | 0.79 | LMNA (0.44) | LMNASMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL5062929 | 0.78 | RAB9A (0.52) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL3078752 | 0.78 | RAB9A (0.52) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL7200135 | 0.78 | RAB9A (0.52) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL5323369 | 0.78 | HPGD (0.49) | LMNASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL5323373 | 0.78 | HPGD (0.49) | LMNASMN1; SMN2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0164389-B1 | PREPARATION OF PHENYL ALANINES BY HYDROGENATION OF PHENYL SERINES | ALKALOIDA VEGYéSZETI GYáR (HU) | 1987-04-01 | — | — | EP | claimed |
| EP-0164389-A1 | PREPARATION OF PHENYL ALANINES BY HYDROGENATION OF PHENYL SERINES. | ALKALOIDA VEGYESZETI GYAR (HU) | 1985-12-18 | — | — | EP | claimed |
| WO-1985002609-A1 | PREPARATION OF PHENYL ALANINES BY HYDROGENATION OF PHENYL SERINES | ALKALOIDA VEGYÉSZETI GYÁR (HU) | 1985-06-20 | — | — | WO | claimed |
| US-9175061-B2 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20110263501-A1 | Growth Hormone Conjugate with Increased Stability | Nono Nordisk Health Care AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| EP-2324056-A1 | GROWTH HORMONE CONJUGATE WITH INCREASED STABILITY | Novo Nordisk Health Care AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010029107-A1 | GROWTH HORMONE CONJUGATE WITH INCREASED STABILITY | NOVO NORDISK HEALTH CARE AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| EP-2040757-A2 | NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION | Novo Nordisk Health Care AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003750-A2 | NEW PROTEIN CONJUGATES AND METHODS FOR THEIR PREPARATION | NOVO NORDISK HEALTH CARE AG (DK) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263501-A1 | Growth Hormone Conjugate with Increased Stability | GHRHR, GHITM, GHSR | LMNA 4242/4885SMN1; SMN2 1929/4885MEN1 1106/4885 |
| US-20110144017-A1 | Protein conjugates and methods for their preparation | PTMS, DNPEP, ANPEP | LMNA 2302/4885SMN1; SMN2 2562/4885MEN1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.